期刊
JOURNAL OF NUCLEAR MEDICINE
卷 54, 期 8, 页码 1195-1201出版社
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.112.114116
关键词
F-18-FDG; prostate; cancer; castrate-resistant; survival
资金
- National Institutes of Health, National Cancer Institute [R01-CA111613]
- National Cancer Institute [P30-CA014089]
The aim of this prospective investigation was to assess the association of parameters derived from baseline F-18-FDG PET/CT with overall survival (OS) in men with castrate-resistant metastatic prostate cancer. Methods: Eighty-seven men with castrate-resistant metastatic prostate cancer underwent F-18-FDG PET/CT and were followed prospectively for OS. Median follow-up in patients who were alive was 22.2 mo (range, 1.6-62.5 mo). OS was defined as the time between the PET/CT imaging or the start of chemotherapy, whichever was later, and death, with patients who were alive censored at the last follow-up date. PET parameters included maximum standardized uptake value (SUVmax) of the most active lesion, sum of SUVmax, and average SUVmax of all metabolically active lesions, after subtraction of patient-specific background-liver average SUV. Comparison of OS was based on univariate and multivariable Cox regression analyses of continuous PET parameters adjusted for standard clinical parameters (age, serum prostate-specific antigen level, alkaline phosphatase, use of pain medication, prior chemotherapy, and Gleason score at initial diagnosis). Survival curves based on Kaplan-Meier estimates are presented. Results: Among the 87 patients, 61 were dead at the time of last follow-up. Median OS was 16.5 mo (95% confidence interval [CI], 12.1-23.4 mo), and the OS probability at 24 mo was 39% +/- 6%. For the univariate analysis, the hazard ratios associated with each unit increase were 1.01 (95% Cl, 1.006-1.02) for sum of SUVmax (P = 0.002), 1.11(95% Cl, 1.03-1.18) for maximum SUVmax (P = 0.010), and 1.13 (95% CI, 0.99-1.30) for average SUVmax (P = 0.095). For the multivariable analysis adjusting for relevant clinical parameters, the continuous parameter sum of SUVmax remained significant (P = 0.053), with a hazard ratio of 1.01(95% Cl, 1.001-1.02). When sum of SUVmax was grouped into quartile ranges, there was poorer survival probability for the patients in the fourth-quartile range than for those in the first-quartile range, with a univariate hazard ratio of 3.8 (95% Cl, 1.8-7.9). Conclusion: Sum of SUVmax derived from F-18-FDG PET/CT contributes independent prognostic information on OS in men with castrate-resistant metastatic prostate cancer, and this information may be useful in assessing the comparative effectiveness of various conventional and emerging treatment strategies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据